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Retinal gene transfer with adeno-associated viral (AAV) vec-
tors holds great promise for the treatment of inherited retinal
degenerations (IRDs). One limit of AAV is its transfer capacity
of about 5 kb, which can be expanded to about 9 kb, using dual
AAV vectors. This strategy would still not suffice for treatment
of IRDs such as Usher syndrome type 1D or Alström syndrome
type I (ALMS) due to mutations in CDH23 or ALMS1, respec-
tively. To overcome this limitation, we generated triple AAV
vectors, with a maximal transfer capacity of about 14 kb. Tran-
scriptomic analysis following triple AAV transduction showed
the expected full-length products along a number of aberrant
transcripts. However, only the full-length transcripts are effi-
ciently translated in vivo. We additionally showed that approx-
imately 4% of mouse photoreceptors are transduced by triple
AAV vectors and showed correct localization of recombinant
ALMS1. The low-photoreceptor transduction levels might
justify the modest and transient improvement we observe in
the retina of a mouse model of ALMS. However, the levels of
transduction mediated by triple AAV vectors in pig retina
reached 40% of those observed with single vectors, and this
bodes well for further improving the efficiency of triple AAV
vectors in the retina.
INTRODUCTION
Inherited retinal degenerations (IRDs), with an overall global preva-
lence of 1/2,000,1 are a major cause of blindness worldwide. IRDs are
mostly monogenic and are caused by mutations in genes mainly ex-
pressed in retinal photoreceptors (PRs; rods and cones) and to a lesser
extent in retinal pigmented epithelium (RPE).2 To date, gene therapy
based on adeno-associated viral (AAV) vectors represents the most
promising therapeutic approach for IRDs. AAVs are (1) safe and
effective when delivered subretinally in patients with Leber congenital
amaurosis type 2, a severe form of inherited childhood blindness3–8
and (2) to date, the most effective gene transfer vector for PRs in
addition to RPE.9–15 However, the relatively small DNA packaging
capacity of AAV, which is considered to be restricted to the size of
the parental genome (4.7 kb),16–19 prevents its application from the
treatment of those IRDs caused bymutations in genes having a coding
sequence (CDS) larger than 5 kb, such as Stargardt disease (STGD1;
MIM_248200), Usher syndrome types IB (USH1B; MIM_276900)
and 1D (USH1D; MIM_601067), or Alström syndrome (ALMS;
MIM_203800), among others.
Dual AAV vectors20–23 have been developed to overcome the limited-
cargo capacity of AAV by splitting a large transgene expression
cassette in two separate halves, each independently packaged in a sin-
gle normal-size (<5 kb) AAV vector.20,21,23,24 The reconstitution of
the full-length expression cassette is achieved upon co-infection of
the same cell by both dual AAV vectors followed by inverted terminal
repeat (ITR)-mediated tail-to-head concatemerization of the 50 and 30
genomes and/or followed by splicing (dual AAV trans-splicing vec-
tors [TS]);20–22,25 homologous recombination between overlapping
regions contained in both the 50 and 30 genomes (dual AAV overlap-
ping vectors)21 or a combination of the two (dual AAV hybrid vec-
tors), where the directional concatemerization can be favored by
the presence of highly recombinogenic sequences.23 We have recently
shown that both dual AAV TS and hybrid AK vectors (that contain
the short AK recombinogenic region from the F1 phage) efficiently
transduce mouse PRs and RPE, and rescue mouse models of
STGD1 and USH1B26 caused by mutations in ABCA4 (ATP-binding
cassette subfamily A member 4; CDS, 6.8 kb) andMYO7A (MYOSIN
VII A; CDS, 6.6 kb), respectively. Robust MYO7A reconstitution by
dual AAV vectors was confirmed in the mouse retina by Dyka
et al.,27 while several examples of dual AAV systems for minidystro-
phin (CDS, 6.2 kb) expression in mouse muscle are available.23,28 The
efficacy of dual AAV vectors, with a maximum transfer capacity of
around 9 kb, opens the venue for further expansion to triple AAV vec-
tors with a theoretical transfer capacity of around 14 kb.
Triple AAV vectors, in principle, would enable the development of
gene therapies for IRDs due to mutations in genes whose CDS is
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larger than 9 kb (herein referred to as large genes). Among those IRDs
are (1) USH1D, a severe form of autosomal recessive blindness-deaf-
ness which accounts for 19%–35% of cases of Usher syndrome
type 129–31 and which is caused by mutations in CDH23 (CDS,
10.1 kb), which encodes for the Cadherin-related family member
2332,33 and (2) ALMS, an autosomal recessive condition, with a prev-
alence of less than one per million34, and characterized by a combina-
tion of features including obesity, insulin resistance, and retinal
dystrophy. ALMS is caused by mutations in ALMS1 (CDS, 12.5 kb),
which encodes for a ciliary/centrosomal protein thought to play a
key role in transport along the PR axoneme.34–38 Triple AAV vectors
have previously been exploited to reconstruct full-length dystrophin
(CDS, 11.1 kb) in the muscle of dystrophic mice.39,40 Low levels of
full-length dystrophin expression were obtained by both TS40 and
hybrid systems.39 These results demonstrated great potential for
testing triple AAV vectors in the retina to restore CDH23 and
ALMS1 gene expression. Indeed, the enclosed and small subretinal
space should favor co-infection and transduction of the same cell
by three independent AAV vectors.
RESULTS
Generation of Single and Triple AAV Vectors
In order to test transduction efficiency mediated by triple AAV
vectors, we generated a reporter protein by fusing the CDS
of EGFP to that of Discosoma red fluorescent protein (DsRed)
(herein referred to as ED) separated by a 13 amino acid spacer.
A triple flag tag (3xflag) was added at the 30 end of ED CDS
(Figure 1A), which was placed under the control of (1) the
ubiquitous cytomegalovirus (CMV) promoter, (2) the PR-specific
human interphotoreceptor retinoid-binding protein (IRBP) pro-
moter,41,42 or (3) the RPE-specific vitelliform macular dystrophy 2
(VMD2) promoter.43 The ED cassettes were either packed in
a single AAV vector or split in three parts, each packed in a
different AAV vector (Figure 1B and Materials and Methods)
from here called ED-AAV 1, ED-AAV 2, ED-AAV 3. Upon
HEK293 transfection with plasmids expressing ED, the ED sponta-
neous fluorescence appeared weaker than the fluorescence detected
when single EGFP- or single DsRed-expressing plasmids were used
(Figure S1).
Figure 1. Schematic Representation of Single and Triple AAV Vectors
Single ED-AAV (A); triple ED-AAVs (B); triple CDH-AAVs (C); triple ALMS-AAVs (D). The position of the epitopes recognized by the antibodies used in this study is indicated.
The vector genome size is depicted above each vector. bGHpA, bovine growth hormone polyadenylation signal; SD, splicing donor signal; SA, splicing acceptor signal; AP,
alkaline phosphatase recombinogenic region; AK, F1 phage recombinogenic region; AB200, ABCA4 recombinogenic region; 3xflag, triple flag tag; CMV, cytomegalovirus;
a-EGFP, anti-EGFP antibodies; a-3xflag, anti-3xflag antibodies; a-CDH23, anti-CDH23 antibodies; a-ALMS1, anti-ALMS1 antibodies.
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Similarly, CDH23-3xflag and ALMS1-3xflag were split in three parts
each cloned in a separate AAV vector (Figures 1C and 1D and Mate-
rials and Methods) from here called CDH-AAV 1, CDH-AAV 2,
CDH-AAV 3, and ALMS-AAV 1, ALMS-AAV 2, ALMS-AAV 3.
CDH-AAV 1 and ALMS-AAV 1 included the ubiquitous CMV and
either the short CMV (shCMV) or the PR-specific human G pro-
tein-coupled receptor kinase 1 (GRK1) promoters, respectively.
For the in vitro experiments, we generated AAV2/2 vectors, which
efficiently transduce HEK293 cells.44 In the experiments performed
in the mouse and pig retinas, we used AAV2/8 vectors, which
efficiently transduce RPE and PRs9–11 but poorly infect HEK293 cells.
Triple ED-AAV Vectors Efficiently Transduce HEK293 Cells
First, we evaluated the efficiency of triple ED-AAV-mediated
large gene transduction in vitro by infecting HEK293 cells with
AAV2/2 vectors at an MOI of 5  104 genome copies (GC)/cell
of each vector. Seventy-two hours after infection, cell lysates were
analyzed and the ED expression was evaluated by western blot
(WB) using anti-3xflag (Figure 2A) or anti-EGFP (Figure 2B) anti-
bodies (please see their specific epitope localization in Figure 1), by
direct microscope imaging (Figure 2C) and by cytofluorimetry. As
shown in Figures 2A and 2B, full-length proteins (#A) of the ex-
pected size (z60 kDa) were detected only following co-infection
with the three ED-AAV vectors. Various shorter products were de-
tected by the anti-3xflag antibodies when ED-AAV 3, which includes
the 3xflag tag, was added to the infection mix (Figure 2A). These
include (1) a product that derives fromED-AAV2+ 3 (#B); (2) a prod-
uct that might derive from the concatemerization of ED-AAV 1 + 3
and the use of an alternative ATG in frame with the 3xflag (#C);
(3) a product from ED-AAV 3 alone (#F); and (4) products that
might represent aggregates of #F (#D and #E). WB with anti-EGFP
antibodies (Figure 2B) confirmed the presence of both full-length
ED (#A) when the 3 ED-AAV vectors were used and the shorter #B
product in the ED-AAV 2 + 3 sample. Interestingly, the relative
amount of the truncated products decreases when the 3 ED-AAV vec-
tors are used.
Figure 2. Triple ED-AAV Vectors Efficiently Transduce ED In Vitro
(A and B)Western blot (WB) analysis of lysates fromHEK293 cells either transfected with pED or infected with triple AAV2/2 vectors encoding for ED and stained with a-3xflag
(A) and a-EGFP (B) antibodies. The arrows on the right indicate the following protein products: #A, ED full-length protein; #B, from AAV 2 + 3; #C, from AAV 1 + 3; #F, from
AAV 3; #D and #E, aggregates of AAV 3. a-3xflag, WB with anti-3xflag antibodies; a-EGFP, WB with anti-EGFP antibodies; a-b-Tubulin, WB with anti-b-Tubulin antibodies,
used as loading control. Neg, not infected cells. The molecular weight ladder is depicted on the left; 20 and 200 mg of proteins for transfected and infected samples,
respectively, were loaded. TheWB images are representative of n = 4 independent experiments. (C) Fluorescent analysis of HEK293 cells infected with triple AAV2/2 vectors
encoding for ED. The scale bar (200 mm) is depicted in the figure. DsRed, Discosoma red fluorescent protein; Merge: overlay of EGFP and DsRed images.
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ED expression was also evaluated by direct imaging of native fluores-
cence (Figure 2C). Double EGFP and DsRed-positive cells could be
detected only when the 3 ED-AAVs were used. Cells that are positive
for either EGFP or DsRed alone were detected when ED-AAV 1 + 2 or
ED-AAV 2 + 3 were respectively used, but they were almost absent in
the ED-AAV 1 + 2 + 3 samples.
The efficiency of triple ED-AAVs transduction was then quantified by
cytofluorimetry, which showed that double EGFP andDsRed-positive
cells were present above background only in single ED-AAV
(46.69% ± 5.66%; n = 4) and in ED-AAV 1 + 2 + 3 (2.78% ±
0.84%; n = 3) samples. Therefore, the efficiency of triple ED-AAVs
transduction is 5.96% ± 1.95% of that of the corresponding single
vector.
Triple CDH- and ALMS-AAV Vectors Efficiently Transduce
HEK293 Cells
HEK293 cells were infected with the various combinations of CDH-
and ALMS-AAV2/2 vectors at an MOI of 5  104 GC/cell and
analyzed 72 hr post-infection. The expression of full-length and trun-
cated products of CDH23 and ALMS1 was evaluated at both tran-
scriptional and translational levels.
cDNAs fromHEK293 infected cells were analyzed by real-time qPCR.
For each transgene, six primers (A/F) were used, each annealing to
one extremity of the three CDSs separately included in each of the tri-
ple vectors (Figure 3A). First, we observed that the real-time qPCR
amplification using primers D (located at the 30 end of vector 2)
and E (located at the 50 of vector 3) following infection with
AAV 2 + 3 is significantly lower than the one obtained when
AAV 1 + 2 + 3 are used (2% for CDH23 and 20% for ALMS1). This
means that amplification with this set of primers can be used as a close
estimate of full-length transcript following concatemerization of the
three vectors. For simplicity, from now on, such measurement will
be set to 1 as reference, and the abundance of the other products
will be presented as fold change relative to the reference. To detect
the transcripts from all possible triple AAV concatemers, the A/F
primers were tested in all possible combinations. The sets of primers
that generated a PCR product with a relative abundance >0.1
compared to full-length are reported in Figure 3B, along with a sche-
matic representation of the corresponding predicted AAV conca-
temer. For both CDH23 and ALMS1 transgenes, amplification of
products with a relative abundance higher than full-length was ob-
tained with the following primer couples: B + C, A + B, B + E, and,
only in the case of ALMS1, C + D (shown in bold in Figure 3B,
“in vitro” column). Direct sequencing of real-time qPCR products re-
vealed that, upon correct assembly of the triple CDH- orALMS-AAV,
correct splicing occurs (data not shown).
As the real-time qPCR analysis cannot reveal the generation of alter-
native splicing within the three CDSs, we additionally performed a
targeted RNA-seq analysis with de novo annotation of the two trans-
genes. The analysis annotated the presence of the full-length tran-
script in both CDH23 (Figure S2A) and ALMS1 (Figure S2B) samples.
Similar to what we observed in the real-time qPCR analysis, the most
represented products derive from the concatemerization of AAV 1 +
3. It is interesting to note that the CDS of CDH-AAV 3 seems to
generate several isoforms as a consequence of alternative splicing.
Following detailed transcriptional characterization of HEK293 cells
infected with triple AAV vectors, we tested the presence of full-length
and truncated CDH23 and ALMS1 protein products. WB analysis of
lysates from infected cells was performed using antibodies (please see
their specific epitope localization in Figure 1) directed to either the
3xflag tag (Figures 4A and 4C) or CDH23 and ALMS1 (Figures 4B
and 4D). In all cases, full-length protein (#A) was detected with
both anti-3xflag and anti-CDH23 or anti-ALMS1 antibodies only
when the three CDH- (Figures 4A and 4B; z360 kDa) or ALMS-
AAVs (Figures 4C and 4D; z461 kDa) were used. Please note that
the shape of the ALMS1 bands in the lanes ALMS-AAV 1 + 2 + 3
may be due to the challenging migration of such high molecular
weight proteins in the SDS-PAGE. In addition to the full-length pro-
teins, several shorter products were observed: (1) a truncated product
(#B) which corresponds to CDH23 C terminus was detected with
anti-3xflag antibodies when CDH-AAV 3 was included in the infec-
tion mix (Figure 4A); (2) only in the sample infected with CDH-
AAV 1 + 3, a smear of bands was observed that was greatly reduced
when the three CDH-AAV vectors were included in the infection mix
(Figure 4A); (3) a truncated product ofz270 kDa (#B) was detected
with anti-3xflag antibodies when ALMS-AAV 1 + 3 was included in
the infection mix (Figure 4C). The two bands of z171 and
z117 kDa present in all lanes of the WB shown in Figure 4D are pre-
sumably due to aspecific antibody binding.
Subretinal Administration of Triple ED-AAVs Results in Full-
Length Transgene Expression in Mouse and Pig Retina
We hypothesized that the enclosed and small subretinal space should
favor co-infection and transduction of the same cell by three indepen-
dent AAV vectors. To evaluate this, we injected subretinally triple
CMV-ED-AAV2/8 vectors (dose of each vector/eye, 4.2  109 GC)
in 4-week-old C57BL/6J mice (n = 7 eyes). Eyes were harvested
2 months later, and we analyzed, on retinal cryosections, the number
of PR cells expressing ED (Figure 5A). We found, in the transduced
area of 5 out of 7 eyes, that 2.9% ± 0.5% were positive for EGFP alone
(which derives from concatemerization of only ED-AAV 1 + 2) and
3.6% ± 0.3% were positive for both EGFP and DsRed (which derives
from concatemerization of ED-AAV 1 + 2 + 3). As no PRs were pos-
itive for DsRed alone (which derives from ED-AAV 2 + 3), we
conclude that the co-expression of EGFP-DsRed indicates full-length
protein expression deriving from proper directional concatemeriza-
tion of ED-AAV 1 + 2 + 3.
To confirm by WB analysis the retinal expression of full-length
ED protein as well as to detect potential byproducts from ED-
AAV 1 + 3 that could not be viewed on retinal histological sections,
the following combinations of triple ED-AAVs (dose of each
vector/eye, 4.2  109 GC) were injected subretinally in 4-week-old
C57BL/6J mice: ED-AAV 1 + 2 + 3 (n = 8 eyes); ED-AAV 2 + 3
www.moleculartherapy.org
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(n = 8 eyes); ED-AAV 1 + 3 (n = 6 eyes); ED-AAV 3 (n = 6 eyes);
single ED-AAV (n = 6 eyes). Eyecups were harvested 2 months
later, and WB analysis was performed using anti-3xflag antibodies.
As shown in Figure 5B, apart from the full-length protein (#A),
when the 3 ED-AAV vectors were included in the mix, an additional
faint band of lower molecular weight was detected (#C), which has a
molecular weight similar to that detected in vitro in the ED-AAV
1 + 3 sample (#C) (Figure 2A). However, this product was present
only in one out of six eyes injected with ED-AAV 1 + 3, confirming
that this is a rare event which was not detected in retinal histological
sections (Figure 5A). The other bands present in ED-AAV 1 + 2 + 3
sample, which are also present in the samples injected with single
ED-AAV, might represent degradation products of the full-length
ED protein.
We then investigated whether triple AAV transduction occurs in
different retinal cell types. Toward this end, 4-week-old C57BL/6J
mice were injected subretinally with three sets of triple ED-AAV vec-
tors, each with a different promoter: CMV, IRBP, and VMD2 at the
doses of 4.2  109, 3.7  109, and 2.4  109 GC/each vector/eye,
respectively. Animals were sacrificed 2 months post-injection, and
protein lysates from eyecups were analyzed by WB, which showed
that full-length ED reconstitution and expression can be driven by
all three promoters, although with different efficiencies. Subretinal
Figure 3. Transcriptomic Analysis following Transduction with Triple AAV Vectors
(A) Schematic representation of triple CDH and ALMS-AAV vectors with primers used for real-time qPCR (A/F). Prom, promoter; CDS, coding sequence; polyA, poly-
adenylation signal; 3xflag, triple flag tag; SD, splicing donor signal; SA, splicing acceptor signal; rec, recombinogenic region. (B) Results of the real-time qPCR analysis
performed on cDNAs from HEK293 cells or mouse eyecups treated with either CDH- or ALMS-AAV 1 + 2 + 3 vectors. The left column shows the vector assembly predicted
on the basis of the set of primers used. The two columns on the right show the abundance of the PCR products relative to full-length detected by the D + E primers. Only
products with a relative abundance >0.1 are shown. Highlighted in italic is the relative abundance of PCR products resulting from the desired AAV directional con-
catemerization. Highlighted in bold are the PCR products with a relative abundance >1.
Molecular Therapy
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injection of triple VMD2-ED-AAV vectors, which includes the RPE-
specific VMD2 promoter, displayed strong protein expression in
10/10 analyzed eyes. The ubiquitous CMV promoter resulted in
slightly higher levels of ED expression compared to VMD2 in 13/18
(72%) analyzed eyes. The IRBP promoter, specific for PR expression,
resulted in faint ED expression in 14/19 (74%) analyzed eyes
(Figure 5C).
To assess if the weak PR transduction observed with the IRBP pro-
moter was due to poor transcriptional activity of the promoter in the
PRs or limited recombination upon co-infection of the three vectors,
we compared the expression of the ED protein encoded by the triple
AAV vectors to the expression by a single AAV vector containing
the same expression cassette (Figures 5D and 5E; Figures S3 and
S4). The experiment was performed with both the CMV (Figures
5D and S3) and IRBP (Figures 5E and S4) promoters, and ED pro-
tein expression was evaluated by WB analysis with anti-3xflag anti-
bodies. WB band intensity showed that, in the case of the CMV
promoter, the level of ED expression obtained with the triple AAV
vectors was 27% ± 6% of the one obtained with the single AAV
vector (n of eyes injected with single AAV = 12; n of eyes injected
with triple AAVs = 14), while this decreased to 2% ± 1% when
IRBP promoter was used (n of eyes injected with single AAV = 6;
n of eyes injected with triple AAVs = 8), thus suggesting that mul-
tiple AAV transduction, rather than the promoter strength, impacts
on mouse PR transduction, as also previously observed with dual
AAV vectors.45
We then evaluated the efficacy of the triple ED-AAV vectors at trans-
ducing PRs in the pig retina. The pig retina is an excellent model to
evaluate viral vector transduction characteristics because of its size,
which is similar to the human retina, and because it is enriched
with cones that are concentrated in a streak-like region similar to
what happens in the primate macula.10We injected subretinally Large
Figure 4. Triple CDH- and ALMS-AAV Vectors Efficiently Transduce CDH23 and ALMS1 In Vitro
(A and B) WB analysis of lysates from HEK293 cells infected with triple AAV2/2 vectors encoding for CDH23 and incubated with either anti-3xflag (A) or anti-CDH23 (B)
antibodies. The arrows on the right indicate the following protein products: #A, full-length CDH23 protein; #B, from AAV 3. (C and D)WB analysis of lysates fromHEK293 cells
infected with triple AAV2/2 vectors encoding for ALMS1 and incubated with either anti-3xflag (C) or anti-ALMS1 (D) antibodies. The arrows on the right indicate the following
protein products: #A, full-length ALMS1 protein; #B, from AAV 1 + 3. a-3xflag, WB with anti-3xflag antibodies; a-CDH23, WB with anti-CDH23 antibodies; a-ALMS1, WB
with anti-ALMS1 antibodies; a-Filamin A, WB with anti-Filamin A antibodies, used as loading control. Neg, cells infected with control AAV2/2-CMV-EGFP vectors. The
molecular weight ladder is depicted on the left, 100 (A), 250 (B), or 200 mg (C and D) of proteins were loaded.
www.moleculartherapy.org
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White pigs with single and triple AAV2/8 vectors encoding ED pro-
tein under the transcriptional control of the PR-specific promoter
IRBP (dose of each vector/eye, 1  1011 GC), and found two out of
three positive eyes in both groups. WB band intensity quantification
showed that ED protein expression with triple AAV vectors was
39% ± 17% (n = 2) of that observed with a single AAV vector (Fig-
ure 6A). Moreover, no truncated products were detected by WB
analysis with anti 3xflag antibodies of neural retina lysates following
subretinal injection of ED-AAV 1 + 2 + 3 (Figure 6B). A shorter
product was observed in the ED-AAV 1 + 3 sample (#E), which is
similar to the one observed in infected cells (#E) (Figure 2A). Overall,
these data suggest that triple AAV vectors transduce pig PRs more
efficiently than mouse, as previously observed with dual AAV
vectors.26
Expression of Therapeutic Transgenes Mediated by Triple AAV
Vectors in the Mouse Retina
We then tested whether subretinal administration of triple AAV2/8
vectors results in expression of CDH23 and ALMS1, which are both
mutated in syndromic forms of retinitis pigmentosa.32–37
Figure 5. Triple AAV Vectors Drive Full-Length Protein Expression in the Mouse Retina
(A) Fluorescence analysis of retinal cryosections from C57BL/6J mice 2 months following subretinal injection of triple ED-AAV2/8 vectors under the control of the ubiquitous
CMV promoter. The pictures with insets at higher magnification are representative of n = 5 injected eyes. Full arrows indicate EGFP and DsRed double-positive PRs. Dashed
arrows indicate EGFP-only positive PRs. The scale bar (20 mm) is depicted in the figure. DsRed, Discosoma red fluorescent protein; Merge, overlay of EGFP, DsRed, andDAPI
images; RPE, retinal pigmented epithelium; ONL, outer nuclear layer. (B) Western blot (WB) analysis of truncated products in eyecup lysates from C57BL/6J mice 2 months
following subretinal injection of the combinations of ED-AAVs. The arrows indicate the following products: #A, ED full-length protein; #C, from AAV 1 + 3. (C) WB analysis of
lysates from C57BL/6J eyecup 2 months following subretinal injection of triple AAV2/8 vectors encoding for ED under the control of the ubiquitous CMV, the RPE-specific
VMD2, and the PR-specific IRBP promoters. The arrow indicates the full-length protein. (D) WB analysis of eyecup lysates fromC57BL/6J mice 2 months following subretinal
injection of single and triple AAV2/8 vectors encoding for ED under the control of the ubiquitous promoter CMV. (E) WB analysis of eyecup lysates from C57BL/6J mice
2months following subretinal injection of single and triple AAV2/8 vectors encoding for ED under the control of the PR-specific promoter IRBP. CMV, cytomegalovirus; VMD2,
vitelliform macular dystrophy 2; IRBP, human interphotoreceptors retinoid binding proteins. a-3xflag, WB with anti-3xflag antibodies; Ponceau, staining with Ponceau, used
as loading control; a-b-Tubulin, WBwith anti-b-Tubulin antibodies, used as loading control. Neg, lysates of eyecups following injectionwith PBS. Themolecular weight ladder
is depicted on the left; 100 (D), 150 (B and C), and 200 (E) mg of proteins were loaded.
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We injected subretinally 4-week-old C57BL/6J mice with either triple
CMV-CDH-AAV (dose of each vector/eye, 2  109 GC) or triple
shCMV-ALMS-AAV vectors (dose of each vector/eye, 2  109 GC).
Animals were sacrificed 2 to 3 months post-injection, and transgene
expression was evaluated by both real-time qPCR andWB. Under the
assumption that the PCR product amplified with the D + E primer
couple derives mostly from full-length transcripts, we compared the
levels of triple AAV-mediated transgene expression to endogenous.
We found that transgenic CDH23 and ALMS1 were 102% ± 55%
and 7% ± 2% of endogenous, respectively (n = 3 eyes/each group).
The apparently different levels of CDH23 and ALMS1 transgene
expression result from different levels of their corresponding endog-
enous transcripts: indeed, endogenous CDH23 is less expressed
(0.005% ± 0.002% of glyceraldehyde 3-phosphate dehydrogenase
[GAPDH]) than endogenous ALMS1 (0.22% ± 0.02% of GAPDH).
Then, the RNA population emerging following triple AAVs subreti-
nal administration was analyzed by real-time qPCR using primer
sets which were previously shown to amplify in vitro transcripts
with a relative abundance >0.1 of full-length (Figure 3B, “in vitro” col-
umn). Among them, the following primer resulted in amplification of
transcripts with a relative abundance higher than full-length: A + B,
A + D, B + C, B + E, C + D, and, only for ALMS1, B + D and
E + F (shown in bold in Figure 3B, “mouse retina” column).
To understand which of these transcripts were translated to detect-
able levels, WB analysis of injected retinas was performed using
anti-3xflag antibodies: a faint but consistent band corresponding
to full-length protein was detected in 11 out of 15 eyes and in 5
out of 8 eyes injected with either CDH- (Figure 7A) or ALMS-
AAVs, respectively (Figure 7B). A shorter product was observed
in the CDH23 sample (#C), which is similar to the most intense
band present in the CDH-AAV 1 + 3 sample in vitro (Figure 4A).
No truncated products were observed by WB in retinas injected
with triple ALMS-AAVs. Immunohistochemistry (IHC) analysis of
retinal cryosections following subretinal injections with triple
CDH-AAVs confirmed expression in PRs (data not shown).
A similar analysis was performed with the set of triple ALMS-
AAV vectors used to rescue the retina of ALMS mice (see next para-
graph and Figure 8A).
Subretinal Administration of Triple AAV Vectors in ALMS Mice
Retinal thickness and electrophysiological responses of Alms1/
were both reduced compared to littermate control (Alms1/+ or
wild-type) mice starting around 4–6 months (data not shown),
similar to what observed in other Alms1/ models.46,47
To test whether the levels of PR transduction obtained with triple
AAV vectors are therapeutically relevant, we have generated triple
ALMS-AAV vectors that include the GRK1 promoter, which restricts
transgene expression to PRs, where ALMS1 is known to localize.48,49
Subretinal injection of these vectors (dose of each vector/eye, 2 109
GC) in 4-week-old C57BL/6J mice results in ALMS1 proper PR
localization 2 months after injection (Figure 8A). We can infer
that transgenic ALMS1 staining derives from full-length protein, as
ALMS1 potential localization signal is predicted to be at the N termi-
nus of the protein50 while the 3xflag tag at the C terminus, and
transcripts from ALMS-AAV 1 + 3 would be out of frame. Triple
GRK1-ALMS-AAV vectors were then injected subretinally in
4-week-old Alms1/mice,51 which received PBS in the contralateral
eye. Four months post-injection, we evaluated by real-time qPCR the
expression of transgenic ALMS1 transcript and found that this was
8.1% ± 6.6% of endogenous. Based on this, we then moved to eval-
uate their impact on Alms1/ retinal morphology and function:
in the Alms1/ eyes injected with triple vectors we observed a
modest, not significant improvement in the outer nuclear layer
(ONL) thickness (Figure 8B), and in the electroretinogram a- (Fig-
ure 8C) and b-wave (Figure 8D) amplitudes between 5 and 7 months
of age (i.e., 4–6 months after gene delivery), which was lost at
9–11 months of age (Figures 8B–8D).
Figure 6. Triple AAV Vectors Drive Full-Length Protein Expression in the Pig
Retina
(A) Western blot (WB) analysis of lysates from Large White pig retina 2 months
following subretinal injection of either single or triple AAV2/8 vectors encoding for ED
under the control of the PR-specific promoter IRBP. The arrow indicates the full-
length protein. (B) WB analysis of truncated products in lysates from LargeWhite pig
retina 2 months following subretinal injection of the combinations of triple ED-AAVs.
Lysates of HEK293 cells infected with an ED-AAV 1 + 2 + 3 are shown on the left as
positive control. The arrows indicate the following products: #A, ED full-length
protein; #E, probably from AAV 3. a-3xflag, WB with anti-3xflag antibodies;
a-b-Actin, WB with anti-b-Actin antibodies, used as loading control. Neg, lysates of
retinas following injection with PBS. The molecular weight ladder is depicted on the
left; 200 mg of proteins were loaded.
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DISCUSSION
While AAV-mediated gene therapy is effective in animal models and
in patients with inherited blinding conditions,3–7,52 its application
to diseases affecting the retina and requiring transfer of sequences
larger than 5 kb is limited by the small cargo capacity of AAV. To
overcome this, dual AAV vectors, which exploit AAV genome ten-
dency to concatemerize upon infection,25,53,54 have been developed
in order to expand AAV DNA transfer capacity to around 9 kb.
Here, we demonstrate both in vitro and in the mouse and pig retina
that similar strategies can be further implemented by including a third
vector in the system, thus expanding AAV transfer capacity to
approximately 14 kb.
Using the ubiquitous CMV as well as the PR- and RPE-specific IRBP
and VMD2 promoters, we showed that full-length gene reconstitu-
tion and expression is more efficient in mouse RPE than in PRs.
This difference is probably due to a combination of the well-known
preferential ability of AAV to transduce RPE than PRs,9 as well as
of poor triple AAV genome recombination in PRs. Weak promoter
activity appears as a less likely explanation, as we observed robust
ED expression from the IRBP promoter using a single AAV vector
(Figure 5E). This low efficiency in PR transduction with triple
AAVs is similar to what we have previously observed with dual
AAV vectors,26 and is consistent with the low levels of homologous
recombination reported in post-mitotic neurons.45 It is important
to note that the spontaneous fluorescence of the fusion protein ED
is weaker than the fluorescence of the single native reporters (Fig-
ure S1). Thus, the actual number of PRs transduced by triple AAV
vectors may be higher than 3.6% observed in Figure 5A.
The percentage of mouse PR transduction is similar to the percentage
of HEK293 cells transduced by triple AAV vectors (2.78% of total cells
or 5.96% of transduced cells) despite the 25–50 times lower MOI pre-
dicted in the retina than used in in vitro infections. Indeed, Ortín-
Martínez et al.55 estimated that the total number of PRs in a mouse
retina is 6.4  106. Considering that we transduce, on average, one-
third of the retina (which corresponds to about 2  106 PRs) we
can infer that the MOI in the retina is between 1,000 and 2,000, as
opposed to 5  104 GC/cell used in vitro. The imaging data only
apparently differ from what we observe in the WB, where the levels
of transgene expression appear weaker in vivo than in vitro
(CDH23, Figure 4A versus Figure 7A; ALMS1, Figure 4C versus Fig-
ure 7B). Indeed, the in vivo WB analyses are performed on material
extracted from whole eyes as opposed to the imaging analysis, which
is conducted on the transduced area: thus, in WB, the transgenic pro-
tein from the transduced area is diluted within untransduced tissue.
Interestingly, while in mouse retina, ED expression observed with tri-
ple IRBP-ED-AAV vectors represented only 2% of that obtained with
single IRBP-ED-AAV, in pig retina this increased to 39%. This is
consistent with our previous results that the relative PR-EGFP expres-
sion obtained upon subretinal delivery of dual AAV vectors is 6% in
mice26 and 40% in pigs of that obtained with single AAV, which was
explained by the higher PR co-transduction rate of two independent
AAVs observed in pigs (74%) than in mice (24%).56 This could be due
to thicker physical barriers in the pig than in the mouse retina that
might limit vector diffusion, thus concentrating the vector in a
smaller area and maximizing co-infection of the same cells by multi-
ple vectors. Also, species-specific differences in the efficiency of both
AAV2/8 transduction and/or vector intermolecular recombination
cannot be excluded. This result is particularly important, considering
that the pig retina is an excellent pre-clinical model with a size and
architecture more similar to the human than the mouse retina.10,57–61
An important concern for clinical use of multiple AAVs is the
possible generation of truncated proteins, which might affect both
safety and functionality of the treatment. We addressed this impor-
tant issue by characterizing both transcripts and translated products
from triple AAV vectors in vitro and in the mouse retina. The in vitro
real-time qPCR and RNA-seq analyses showed that most of the
products expressed at high levels are predicted to be generated by
similar AAV genome concatemers between triple CDH- and
ALMS-AAVs (Figure 3). Interestingly, in addition to the products
from concatemers containing either simultaneously the promoter
Figure 7. Subretinal Administration of Triple AAV
Vectors Results in Full-Length CDH23 and ALMS1
Protein Expression in the Mouse Retina
(A) Western blot (WB) analysis of eyecup lysates from
C57BL/6J mice 3 months following subretinal injection of
triple AAV2/8 encoding for CDH23 under the control of
the ubiquitous CMV promoter. The arrows on the right
indicate the following products: #A, full-length proteins;
#C, probably from AAV 1 + 3. (B) WB analysis of eyecup
lysates from C57BL/6J mice 3 months following sub-
retinal injection of triple AAV2/8 encoding for ALMS1
under the control of the ubiquitous short CMV promoter.
The arrow on the right indicates full-length ALMS1.
a-3xflag, WB with anti-3xflag antibodies; a-Dysferlin, WB
with anti-Dysferlin antibodies, used as loading control.
Neg, lysates of eyecups following injection with PBS. The
molecular weight ladder is depicted on the left; 200 mg of
proteins (A) or the whole-eyecup lysates (B) were loaded.
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and the polyadenilation signal (i.e., AAV 1 + 3 and AAV 1 + 2 + 3) or
the promoter alone (AAV 1 with or without AAV 2), we found high
levels of expression from AAV 2 in the case of ALMS1. It is possible
that, in this case, the ITR-mediated promotorial activity62 combined
with stability of the transcript results in high levels of aberrant tran-
script. However, the absence of a Kozak consensus sequence with a
close-by ATG suggests that this transcript should not be efficiently
translated.
Importantly, the translation of the various aberrant transcripts de-
tected appears to be inefficient, as only few truncated products, mostly
predicted from AAV 1 + 3 concatemerization, were observed in the
WB analysis of cells infected with triple AAVs. One exception appears
to be a protein product that is predicted to derive from CDH-AAV 3
that was detected, despite its low level of transcription, suggesting a
high stability of this product. Interestingly, the various alternative
CDH23 isoforms shown by RNA-seq (Figure S2A) may be respon-
sible for the great number of protein products present in CDH-
AAV 1 + 3 sample. One important phenomenon that we have
observed is that most of the truncated products present when only
1 or 2 vectors were used for the infection decreased when the third
vector was added (Figures 2A–2C and 4A). This suggests that when
evaluating the potential toxicity of triple AAV vectors, this should
be done in the context of all vector components and not be extrapo-
lated from combinations of single AAV.
The levels of aberrant proteins observed in vivo was even lower than
that observed in vitro (Figures 5B and 7). This is interesting, as some
of the transcripts detected by real-time qPCR in the mouse retinas
transduced with triple AAVs were more abundant than in cells
(primer sets A + B, A +D, B + C, B +D, C +D, and E + F) and suggests
a more stringent protein quality control in live animals than in
HEK293 cells. The only exception seems the detection of EGFP-
only positive cells in retinal sections of animals injected with
ED-AAV 1 + 2 + 3 (Figure 5A). This could be the result of
products from ED-AAV 1 + 2 that are particularly stable and might
accumulate over the 2-month time of the in vivo but not of the shorter
in vitro experiments (Figure 2C). The low sensitivity of the WB with
anti-EGFP antibodies may explain why the product from ED-AAV
1 + 2 is only detected by direct fluorescence analysis of retinal cryo-
sections. In addition, the presence of protein products deriving
from alternative open reading frames (ORFs), which would not be de-
tected with the set of antibodies used in this study, cannot be excluded
at this point.
Figure 8. Alms1–/– Retinal Structure and Function following Subretinal Delivery of Triple AAV Vectors
(A) Immunohistochemical (IHC) analysis with anti-3xflag antibodies of retinal cryosections from C57BL/6J mice 2months following subretinal injections of either triple AAV2/8
encoding for ALMS1 under the control of the PR-specific GRK1 promoter (top panels) or PBS (bottom panels). The pictures are representative of n = 4 injected eyes. The
scale bar (20 mm) is depicted in the figure. Merge, overlay of DAPI and ALMS1. ONL, outer nuclear layer; OS, outer segment. (B) Spectral domain optical coherence to-
mograms (SD-OCT) analysis of Alms1/mice injected subretinally with either triple GRK1-ALMS-AAV vectors (white bars) in one eye or PBS in the contralateral eye (black
bars). Results are reported as means ± SE. (C and D) Electroretinographic analysis of a-wave (C) and b-wave (D) light responses of Alms1/mice injected subretinally with
either triple GRK1-ALMS-AAV vectors (white bars) or PBS in the contralateral eye (black bars). Results are reported as means ± SE. Light intensity of 20 cd s/m2 (a-wave);
background white light of 50 cd s/m2 and light intensity of 20 cd s/m2 (b-wave).
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In agreement with the low levels of unexpected protein products in
the mouse retinas, no evident signs of toxicity were observed by op-
tical coherence tomography analysis (data not shown) in animals in-
jected 2 months before with either CDH- or ALMS-AAV 1 + 3, the
combination of viruses that produced the highest levels of truncated
products in vitro. Nevertheless, before considering the system for a
therapeutic use in humans, more efforts should be focused to evaluate
potential toxicity of truncated products, as well as strategies to elim-
inate them, such as the inclusion of degradation signals strategically
placed in the vectors, which we have recently demonstrated to be
effective at abolishing selectively truncated proteins from dual AAV
vectors.63
The possibility to further expand the dual AAV vectors to triple in or-
der to express larger genes has been recently evaluated in mouse
muscle39,40 for dystrophin transduction, but with poor efficiency.
Although a direct comparison between the triple AAV vectors used
in that study and our triple AAV vectors is difficult, the levels of
full-length transgene expression we achieve in the retina with triple
AAV vectors appear to be higher, as we are able to detect full-length
protein reconstitution by WB, in addition to fluorescence analysis on
histological sections that were used for dystrophin detection in Lostal
et al.39 and Koo et al.40
The expression levels achieved inmice with triple ED-AAV compared
to single ED-AAV vectors are similar to those that we previously
observed with dual AAV vectors, both in the mouse and in the pig
retina,26 suggesting that, in the subretinal space, co-infection by mul-
tiple AAV vectors is favored.
If we consider that 3.6% of PRs are transduced by triple AAV vectors
following subretinal administration in mice (Figure 5A) and we
calculate the transgene expression levels per cell, we find that the
102% of endogenous CDH23 achieved with triple CDH-AAVs corre-
sponds to around 3,000% per cell. This is, however, due to the low
levels of endogenous CDH23 expression in mice (where it reaches
only 0.005% of GAPDH levels) but not in humans64 (http://retina.
tigem.it). If we, instead, consider ALMS1, whose endogenous levels
are higher than CDH23 and reach 0.22% of GAPDH, the levels of re-
combinant ALMS1, which are 7%–8% of endogenous, correspond to
approximately 200% per cell. In essence, the levels of CDH23 and
ALMS1 transgene expression from triple AAV vectors relative to
GAPDH are similar, while endogenous ALMS1 is expressed at higher
levels than CDH23 in mice.
Mice with ALMS146 but not CDH2365 deficiency present with PR
degeneration. To understand whether the transduction levels from
triple AAV vectors may be therapeutically relevant, we have treated
Alms1/ mice with subretinal injections of triple GRK1-ALMS-
AAV vectors, but, besides a transient improvement, we did not
observe any significant amelioration of the phenotype. After confirm-
ing that transgenic ALMS1 is properly expressed in PRs at levels
around 8% of endogenous, there could be several reasons that justify
this lack of therapeutic efficacy: (1) as we have transferred the human
ALMS1 transgene inAlms1/mice, we cannot exclude that interspe-
cies differences might be responsible for low therapeutic efficacy;
(2) the non-cell-autonomous PR degeneration described in retinitis
pigmentosa66 may as well account for the lack of therapeutic effect;
and (3) as observed with triple ED-AAVs, only 3.6% of PRs are trans-
duced (Figure 5A), and such fraction might not be sufficient to detect
a significant rescue. It is possible that higher levels of transduction
may improve the efficacy of triple AAV vector. This could be obtained
(1) with higher vectors doses, (2) with more efficient AAV serotypes
than those used here (i.e., AAV Y444, 500, 730F with mutated tyro-
sine residues),67,68 (3) by enlarging the transduced area with a
different injection technique (i.e., double injection) or by intravitreal
injection of highly penetrating serotypes such as AAV7m8,69 (4) by
using a more potent expression cassette than the one used in this
work, or (5) by co-injection of AAV transduction enhancers (i.e., pro-
teasome inhibitors).70–72 Although these levels of rescue appear insuf-
ficient inAlms1/mice, it is important to note that, similar to what is
observed with dual AAV vectors, the level of pig PR ED transduction
by triple versus single AAV2/8 vectors is higher than in mice, which is
promising in view of future therapeutic applications, given the closer
similarity between human and pig than mouse retina.
Overall, our data demonstrate that triple AAV vectors drive large
gene reconstitution both in vitro and in vivo and that this approach
leads to the reconstitution of expression of large genes mutated in
IRDs like USHID or ALMS, thus extending AAV transfer capacity
up to 14 kb in the retina. This bodes well for the development of triple
AAV vectors for other retinal and non-retinal conditions, which
require transfer of such large sequences.
MATERIALS AND METHODS
Generation of AAV Vector Plasmids
The plasmids used for AAV vector production derived from the
pAAV2.173 plasmids that contain the ITRs of AAV serotype 2.
The EGFP-DsRed-AAV (ED-AAV) vectors were generated by cloning
Discosoma red fluorescent protein (DsRed) CDS (675 bp), from the
pDsRed-Express2 plasmid (#632535; Clontech, Saint-Germain-en-
Laye, France) after the EGFP CDS (717 bp) of pAAV2.1-CMV-
EGFP plasmid73 separated by a 39-bp spacer and followed by a 3xflag
sequence and the bovine growth hormone polyadenylation signal
(bGHpA).
To generate triple ED-AAV vector plasmids, the ED CDS was split
into three constructs: the first one (ED-AAV 1) containing the pro-
moter and the N-terminal EGFP CDS74 (bp 1–393), the second one
(ED-AAV 2) containing the C-terminal EGFP CDS74 (bp 394–717)
plus the N-terminal DsRed CDS (FJ226077, bp 1–307), and the last
one (ED-AAV 3) containing the C-terminal DsRed CDS (FJ226077,
bp 308–675) plus the 3xflag.
As recombinogenic regions at the 30 end of ED-AAV 1 and 50 end
of ED-AAV 2, we used the AK sequence, derived from the
phage F1 genome (J02448.1, bp 5,850–5,926), which we previously
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demonstrated to be effective in the context of dual AAV vectors.26 As
a second recombinogenic region (at the 30 end of ED-AAV 2 and
50 end of ED-AAV 3), we used a 200-bp sequence (NM_000350.2,
bp 3,103–3,302) derived from the human ATP-binding cassette,
sub-family A 4 gene (ABCA4), which we found to be recombinogenic
in dual overlapping AAV vectors (AB200; data not shown).
To generate plasmids for triple CDH- and ALMS-AAV vectors, the
three fragments for each CHD23 (AF312024.1) and ALMS1 isoform 1
(NM_015120.4) were obtained by gene synthesis (MWG, now Euro-
fins Genomics, Ebersberg, Germany). CDH- and ALMS-AAV 1
contain the N-terminal CDS (CDH23, AF312024.1, bp 1–3,369;
ALMS1, NM_015120.4, bp 112–4,188); CDH- and ALMS-AAV 2
contain the body of the CDS (CDH23, AF312024.1, bp 3,370–6,712;
ALMS1, NM_015120.4, bp 4,189–8,452); and CDH- and ALMS-
AAV 3 contain the C-terminal CDS (CDH23, AF312024.1, bp
6,713–10,065; ALMS1, NM_015120.4, bp 8,453–12,618) followed by
a 3xflag tag and the bGHpA.
Note that the CDH23 CDS was split at a natural exon-exon junction,
while this was not possible for ALMS1, due to the exon length. More-
over, in both systems, fragment 1 and fragment 3 were designed in
order to generate out-of-frame transcripts in case of undesired
concatemerization.
The AK recombinogenic sequence was placed at the 30 of both
CDH- and ALMS-AAV 1 and at the 50 of CDH- and ALMS-
AAV 2. In the CDH23 expression system, we placed the AP
sequence (NM_001632.4, bp 1,802–1,516) derived from the human
placental alkaline phosphatase gene75 at the 30 of CDH-AAV 2 and
at the 50 of CDH-AAV 3, which results in levels of CDH23 expres-
sion higher than with AB200 (data not shown). Due to size
constraint, no recombination signals were placed at the 30 of
ALMS-AAV 2 nor at the 50 of the ALMS-AAV 3; full-length gene
reconstitution, in this case, relies exclusively on ITR-mediated
joining followed by splicing.
The splice donor (SD) and splice acceptor (SA) signals contained in
triple AAV vector plasmids are as follows: 50-GTAAGTATCAAGGT
TACAAGACAGGTTTAAGGAGACCAATAGAAACTGGGCTTGT
CGAGACAGAGAAGACTCTTGCGTTTCT-30 (SD); 50-GATAGG
CACCTATTGGTCTTACTGACATCCACTTTGCCTTTCTCTCCA
CAG-30 (SA).
The ubiquitous CMV promoter is the one contained in pAAV2.1-
CMV-EGFP;73 the ubiquitous shCMV promoter is the one described
in Pellissier et al.76; the PR-specific human IRBP (X53044.1, bp
2,603–2,837) and the human GRK1 promoter (AY327580.1, bp
1,793–2,087) have been both described to drive high levels of com-
bined rod and cone PR transduction in various species;14,41,42 the
RPE-specific VMD2 promoter (NG_009033.1, bp 4,870–5,516) corre-
sponds to the previously described EcoRI-XcmI promoter fragment43
andwas amplified fromhuman genomicDNA. The details of the clon-
ing strategies as well as plasmid sequences are available upon request.
AAV Vector Production and Characterization
AAV vectors were produced by the TIGEM AAV Vector Core by tri-
ple transfection of HEK293 cells followed by two rounds of CsCl2 pu-
rification.77 For each viral preparation, physical titers (GC/mL) were
determined by averaging the titer achieved by dot-blot analysis78 and
by PCR quantification using TaqMan (Applied Biosystems, Carlsbad,
CA, USA).77 The probes used for dot-blot and PCR analyses were de-
signed to anneal with the promoter for the 50 vector, the bGHpA re-
gion for the 30 vectors, and within the gene for the body vectors. The
length of probes varied between 200 and 700 bp.
Transfection and AAV Infection of HEK293 Cells
HEK293 cells weremaintained in DMEMcontaining 10% fetal bovine
serum (FBS) and 2mML-glutamine (Gibco, Thermo Fisher Scientific,
Waltham,MA, USA). Depending on the experiment, cells were plated
in 6-well plates (1 106 cells/well), 24-well plate (2.5 105 cells/well),
or 8-chamber (1 105 cells/well) and transfected 16 hr later with the
plasmids encoding for the desired transgene using the calcium phos-
phatemethod (1 to 2mg/1 106 cells); mediumwas replaced 4 hr later.
For AAV infection, plated cells were first transfected with
1.5 mg/1  106 cells of pDeltaF6 helper plasmid, which contains the
Ad helper genes.79 After 4 hr, cells were washed once with serum-
free DMEM and incubated with AAV2/2 vectors (MOI 5  104 GC/
cell of each vector) in a final volume of 700 mL of serum-free DMEM.
Two hours later, 1.3 mL of complete DMEM was added to the cells.
To increase transgene expression, 7.5 mM Calpain inhibitor I ([PI]
A6185; Sigma-Aldrich, St. Louis, MO, USA), which is known to in-
crease AAV-mediated transduction,80 was added either once after
infection with triple ED- and CDH-AAVs or daily after infection
with triple ALMS-AAVs.
Animal Models
Mice were housed at the Institute of Genetics and Biophysics animal
house (Naples, Italy) and maintained under a 12-hr light/dark cycle.
C57BL/6J mice were purchased from Harlan Italy SRL (Udine, Italy).
ALMS (referred as Alms1/) mice were imported from The Jackson
Laboratory. The mice were maintained by crossing heterozygous fe-
males with heterozygous males. The Alms1/ mouse harbors the
chemically-induced Alms1 c.1080 + 2T > C splice mutation
(exon 6-intron 6 splice junction) predicted to result in a frameshift
and truncation of ALMS1.51 The genotype of mice was confirmed
by PCR analysis on genomic DNA (extracted from the mouse tail
tip) followed by DNA sequencing. The primers used for the PCR
amplification are as follows:
Fw: 50-GGTGCACAGAGTGAAAGAATTGC-30
Rev: 50-ACTTACCAGTTAAGCCTTGTAGG-30,
which generate a product of 147 bp that was subsequently sequenced
using the Fw primer.
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The Large White female pigs (Azienda Agricola Pasotti, Imola, Italy)
used in this study were registered as purebred in the LWHerd Book of
the Italian National Pig Breeders’ Association and were housed at the
Centro di Biotecnologie A.O.R.N. Antonio Cardarelli (Naples, Italy)
and maintained under a 12-hr light/dark cycle.
Subretinal Injection of AAV Vectors in Mice and Pigs
This study was carried out in accordance with the Association for
Research in Vision and Ophthalmology Statement for the Use of An-
imals in Ophthalmic and Vision Research and with the Italian Min-
istry of Health regulation for animal procedures (Ministry of Health
authorization number 147/2015-PR). Surgery was performed under
general anesthesia, and all efforts were made to minimize animal
suffering. Mice (4 to 5 weeks old) were anesthetized with an intraper-
itoneal injection of 2 mL/100 g body weight of ketamine/xylazine,
then AAV2/8 vectors were delivered subretinally via a trans-scleral
trans-choroidal approach, as described by Liang et al.81 Eyes were in-
jected with 1 mL of vector solution. The AAV2/8 doses (GC/eye) var-
ied across different mouse experiments, as described in the Results
section. PI, at a final concentration of 30 mM, was added to the vector
mix in mouse eyes intended for histology, real-time qPCR, and in
3 out of 15 eyes injected with triple CDH-AAV vectors and destined
for WB analysis.
Subretinal delivery of AAV2/8 vectors to the pig retina was performed
as previously described.10 Eyes (n = 3) were injected with 100 mL of
AAV2/8 vector solution. The AAV2/8 dose was 1  1011 GC of
each vector/eye; thus, co-injection of triple AAV vectors resulted in
a total of 3  1011 GC/eye.
WB Analysis
Samples (HEK293 cells plated in 6-well plates or eyecups [cups +
retinas]) for WB analysis were lysed in radio-immunoprecipitation
assay (RIPA) buffer (50 mM Tris-HCl [pH 8.0], 150 mM NaCl,
1% NP40, 0.5% Na-deoxycholate, 1 mM EDTA, 0.1% SDS
[pH 8.0]) to extract ED, CDH23, and ALMS1 proteins from
HEK293 cells and eyecups. Lysis buffers were supplemented with
protease inhibitors (Complete Protease inhibitor cocktail tablets;
Roche, Basel, Switzerland) and 1 mM phenylmethylsulfonyl. After
lysis, ED, CDH23, and ALMS1 samples were denatured at 99C
for 5 min in 1 Laemmli sample buffer. For ALMS1, 1 Laemmli
sample buffer was supplemented with 4 M urea. Lysates were sepa-
rated by 12% (ED samples), 6% (CDH23 samples), or gradient
(#4561086; Bio-Rad, Hercules, CA, USA) 4%–15% (ALMS1 sam-
ples) SDS-PAGE.
The antibodies and dilutions used for immunoblotting are as follows:
anti-EGFP (1:1,000, ab1218; Abcam, Cambridge, UK); anti-3xflag
(1:1,000, A8592; Sigma-Aldrich, St. Louis, MO, USA); anti-CDH23
(1:500, sc-166005, Santa Cruz Biotechnology, Dallas, TX, USA);
anti-ALMS1 (1:1,000, polyclonal; ab4306, Abcam, Cambridge, UK);
anti-b Tubulin (1:3,000, T5201; Sigma Aldrich, St. Louis, MO,
USA); anti-Filamin A (1:1,000, #4762; Cell Signaling Technology,
Danvers, MA, USA); anti-Dysferlin (1:500, Dysferlin, clone Ham1/
7B6, MONX10795; Tebu-bio, Le Perray-en-Yveline, France); anti-
b-Actin (1:1,000, NB600-501; Novus Biological, Littleton, CO, USA).
Notably, the epitope to which the monoclonal anti-EGFP antibodies
were raised has not been disclosed by the company; however, we
deduced that it maps to the C terminus of EGFP based on the pattern
observed in the WB analysis in Figure 2B.
The quantification of ED bands detected byWB was performed using
ImageJ software (http://rsbweb.nih.gov/ij/); to compare data across
different experiments, in each WB, the average intensity of the bands
deriving from single AAV-transduced eye was set as 1, and the inten-
sity of triple AAV transduced eye was divided by that of single AAV-
transduced eye and calculated accordingly.
Histology and Light and Fluorescence Microscopy
To evaluate ED expression in vitro, HEK293 cells, plated in 8-cham-
bers at a density of 1 105, were infected as previously described. Sev-
enty-two hours post-infection, cells were washed once with PBS, fixed
for 7 min with 4% paraformaldehyde (PFA) in PBS, washed three
times with PBS, and mounted with Vectashield with DAPI (Vector
Lab, Peterborough, UK). Cells were analyzed under the Axio
Observer Z1 (Carl Zeiss, Oberkochen, Germany) equipped with
ZEN software (Carl Zeiss) and using appropriate excitation and
detection settings for EGFP, DsRed, and DAPI.
To evaluate transgene expression in histological sections, C57BL/6J
mice were injected subretinally with triple AAV vectors (supple-
mented with PI at a final concentration of 30 mM). Two months later,
mice were sacrificed and eyes were fixed in 4% paraformaldehyde
overnight and infiltrated with 30% sucrose overnight; the cornea
and the lens were then dissected, and the eyecups were embedded
in optimal cutting temperature compound (O.C.T. matrix; Kaltek,
Padua, Italy). Ten-micrometer-thick serial retinal cryosections were
cut along the horizontal meridian, progressively distributed on slides,
and mounted with Vectashield with DAPI (Vector Lab, Peterbor-
ough, UK). Then, the cryosections were analyzed under the confocal
LSM-700 microscope (Carl Zeiss, Oberkochen, Germany) using
appropriate excitation and detection settings.
For assessment of PR transduction in mouse retinal cryosections
following triple ED-AAV administration, a single section/eye within
the transduced area was selected; the whole slice was acquired at
40 magnification and then analyzed using ImageJ software
(http://rsbweb.nih.gov/ij/). A minimum of 600 PRs, identified by
DAPI staining, were counted for each eye. PRs with signal compatible
with EGFP and DsRed co-expression were unequivocally identified
based on their identical shape on picture micrographs of the same
field.
In the case of fluorescent IHC staining of ALMS1, sections were
washed in PBS for 10 min and were permeabilized and blocked
with 0.3% Triton X-100, 5% next-generation sequencing (NGS),
3% BSA in PBS for 3 hr, then the sections were pre-treated with
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Avidin/Biotin (SP-2001, Vector Lab, Peterborough, UK) according to
manufacturer’s instructions. Sections were incubated overnight
with anti-3xflag antibodies (1:200 F1804 Sigma-Aldrich, St. Louis,
MO, USA). Endogenous peroxidase were blocked with 0.3%
hydrogen peroxide (H1009, Sigma-Aldrich, St. Louis, MO, USA).
Signal was developed using the Vectastain ABC kit (PK-6200 Vector
Laboratories, CA, USA) followed by the SuperBoost Tyramide signal
amplification (B40942, Thermo Fisher Scientific, Waltham, MA,
USA) according to the manufacturer’s instructions. Stained sections
were mounted with Vectashield with DAPI (Vector Laboratories,
CA, USA). Cryosections were analyzed under the confocal LSM-
700 microscope (Carl Zeiss, Oberkochen, Germany) and acquired
at 63 magnification.
Cytofluorimetric Analysis
HEK293 cells, plated in 6- or 24-well plates, were washed once with
PBS, detached with trypsin 0.05% EDTA (Thermo Fisher Scientific,
Waltham, MA USA), washed twice with PBS, and resuspended in
PBS 5% FBS, 2.5 mM EDTA. Cells were analyzed on a BD FACS
ARIA III (BD Biosciences, San Jose, CA, USA) equipped with BD
FACSDiva software (BD Biosciences) using appropriate excitation
and detection settings for EGFP and DsRed. Thresholds for fluores-
cence detection were set on not infected cells, and a minimum of
10,000 cells/sample were analyzed.
RNA Extraction, cDNA Production, and Reverse Transcription
Analysis
Total RNA was extracted using the RT-PCR RNeasy MiniKit
(QIAGEN, Milan, Italy) from either HEK293 cells plated in 6- or
24-well plates and infected or not with triple AAV vectors or mouse
eyecups or retina. RNA (500 ng from cells or eyecups and 360 ng
from retina) was submitted to DNase I digestion (RNase Free
DNase set; QIAGEN) and 20 mL cDNA was generated using the
SuperScript III Reverse Transcriptase kit (Thermo Fisher Scientific,
Waltham, MA, USA) using oligo dT primers. For each sample,
the same amount of RNA did not receive the retrotranscriptase
enzyme and was used as a control for genomic DNA contamina-
tion. Primers for real-time qPCR were designed using the bio-
informatic program “Primer Blast” (https://www.ncbi.nlm.nih.gov/
tools/primer-blast/) and purchased from Eurofins Genomics (Euro-
fins Genomics, Ebersberg, Germany; Table S1). Serial dilutions of
the cDNAs obtained from cells infected with either triple CDH-
or ALMS-AAV 1 + 2 + 3 were used to measure the primer effi-
ciency, which was between 1.75 and 2.25 for all primer sets shown
in Figure 3B. SybrGreen real-time qPCR kit was purchased from
Roche (Roche, Monza, Italy) and used following the manufacturer’s
protocol on the LyghtCycler 96 system (Roche). Five microliters of
diluted cDNA (1:25 to 1:50 for in vitro experiments and 1:5 for the
in vivo experiments) and 10 pmol of primers were used for PCR in a
total volume of 20 mL. Thermal cycling for all genes initiated with
an initial denaturation step at 95C for 5 min, followed by 45 cycles
with denaturation at 95C for 10 s, annealing at 60C for 20 s, and
extension at 72C for 20 s. Expression data were then normalized
versus the corresponding housekeeping genes (h-b-ACTIN for
HEK293 cells and mouse GAPDH (mGAPDH) for eyecups and
retinas).
RNA-Seq Libraries Preparation and Sequencing
A total of 47.5 ng of RNAwas used as input for the synthesis of cDNA
with the SMART-Seq v4 Ultra Low Input RNA Kit for Sequencing
(Takara Bio USA, Mountain View, CA, USA). Manufacturer sug-
gested protocol was followed, with minor modifications. The second
strand synthesis of cDNA was performed by replacing the SMART-
Seq v4 Oligo with custom primers specific for the transgenes of inter-
est (CDH23 oligo, 50-AAGCAGTGGTATCAACGCAGAGTacttgtt
gatctccgaagataccc-30; ALMS1 oligo, 50-AAGCAGTGGTATCAACG
CAGAGTtagtggtggaggaagtagaggag-30 [bp in capital letters belong to
the RNA-seq adaptor]).
Seventy-five pg of cDNA generated with SMART-Seq v4 Kit were
used for library preparation using the NEXTERA XT DNA Library
Preparation kit (Illumina, San Diego, CA, USA), following the sug-
gested protocol.
Samples were sequenced using NextSeq 500/550 Mid Output v2 kit in
a 150 + 150 paired-end run. The data were deposited in GEO:
GSE107173.
RNA-Seq Analysis
Sequence reads were trimmed using Trim Galore! software (https://
www.bioinformatics.babraham.ac.uk/projects/trim_galore/) to re-
move adaptor sequences and low-quality end bases and then analyzed
using the “new tuxedo” software suite.82 The idea was to generate a
custom reference with a “genomic” sequence of the three vector in-
serts where to align the reads. The expected full-length transcript
was used as known reference, but the aligner software was allowed
to introduce new splicing junctions and generate also alternative tran-
scripts if supported by reads (Figure S2).
First, the custom reference sequence was built to perform the viral
vector library sequences alignment. For each transgene, the
sequence of the three vector inserts were pasted sequentially side
by side, separated by a stretch of N bases as spacers to simulate a
“genomic” sequence and then added to the human genome (build
hg19) as separate contigs. The ITR ends were not included to reduce
the possibility of aberrant splicing junctions due to mis-aligned
repeated reads. The relative coordinates of the actual CDSs of
each transgene were used as reference of a single transcript
composed of three exons. The first exon start and the last exon
end bases were defined to coincide respectively with the beginning
of the specific PCR primer and the expected transcription stop
signal, in order to reproduce the expected drop in coverage of the
aligned reads due to library construction, to minimize the genera-
tion of alternative predicted transcripts only differing from the
reference by the start or end coordinates.
Then the analysis was performed following the protocol described in
Pertea et al.82 Reference-guided alignment was performed with
www.moleculartherapy.org
Molecular Therapy Vol. 26 No 2 February 2018 537
HISAT283 followed by transcript assembly with Stringtie.84 The as-
sembly generated for each sample can be slightly different due to
the actual coverage of exons and reads spanning exon-exon junctions,
so the individual assemblies of each sample were merged into a com-
mon consensus with the Stringtie merge function to make them com-
parable. The expression levels of each transcript of the assembled
consensus were then estimated with a final run of Stringtie used to
count reads supporting each transcript without allowing the annota-
tion of any further isoform. The R/Biocondictor package Ballgown85
was then used to visualize results and extract the raw counts and
normalization was performed with DESeq.86
To estimate the relative abundance of each annotated alternative iso-
form, their normalized counts were divided by the corresponding full-
length one and the ratios were averaged among three replicate
samples.
Spectral Domain Optical Coherence Tomography
Spectral domain optical coherence tomography (SD-OCT) images
were obtained using the Bioptigen Spectral Domain Ophthalmic Im-
aging System (SDOIS; Envisu R2200, Bioptigen, Morrisville, NC,
USA). ALMS mice were anesthetized and pupils were dilated by
applying 1–2 drops of topical 0.5% tropicamide (Visufarma, Rome,
Italy). To prevent corneal desiccation during the procedure, topical
lubricant eye drops (Recugel; Bausch & Lomb, Rochester, NY,
USA) were applied bilaterally with a small brush. Mice were posi-
tioned into the animal imaging mount and rodent alignment stage
(AIM-RAS; Bioptigen, Morrisville, NC, USA); the laser source was
placed in front of the mouse, and images were acquired by the
InVivoVue Clinic software (Bioptigen, Morrisville, NC, USA). Three
images, one central, one superior, and one inferior to the optic nerve,
were taken from each eye. ONL thickness was manually measured
three times from each OCT scan image and averaged.
Electrophysiological Recordings
For electroretinographic analyses, ALMSmice were dark-adapted for
3 hr. Mice were anesthetized and positioned in a stereotaxic appa-
ratus, under dim red light. Their pupils were dilated with a drop of
0.5% tropicamide (Visufarma, Rome, Italy), and body temperature
was maintained at 37.5C. Light flashes were generated by a Ganzfeld
stimulator (CSO, Costruzione Strumenti Oftalmici, Florence, Italy).
The electrophysiological signals were recorded through gold-plate
electrodes inserted under the lower eyelids in contact with the cornea.
The electrodes in each eye were referred to a needle electrode inserted
subcutaneously at the level of the corresponding frontal region.
The different electrodes were connected to a two-channel amplifier.
After completion of responses obtained in dark-adapted conditions
(scotopic), the recording session continued with the purpose of dis-
secting the cone pathway mediating the light response (photopic).
To minimize the noise, different responses evoked by light were aver-
aged for each luminance step. The maximal scotopic response of rods
and cones was measured in dark conditions (scotopic) with two
flashes of 0.7 Hz and a light intensity of 20 cd s/m2, photopic cone re-
sponses were isolated in light conditions with a continuous back-
ground white light of 50 cd s/m2, with 10 flashes of 0.7 Hz and a light
intensity of 20 cd s/m2.
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Figure S1.  The EGFP-DsRed-3xflag (ED) protein is less fluorescent than the corresponding native 
EGFP and DsRed reporters. 
Fluorescence analysis of HEK293 cells transfected with plasmids encoding either native EGFP (pEGFP), 
native DsRed (pDsRed) or the EGFP-DsRed-3xflag reporter protein construct (pED). EGFP, native EGFP 
fluorescence; DsRed, native DsRed fluorescence; merge: overlay of EGFP and DsRed. The scale bar (200 
µm) is depicted in the figure. 
Figure S2. Alternative transgene isoforms annotated by RNA-Seq analysis.  
For each transgene, the alternative isoforms are plotted below the full-length transcript. The relative abundance is quantified by 
mean and standard error of the normalized count ratio vs the full-length among 3 replicates. 
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Figure S3. Comparison between single and triple CMV-ED-AAV2/8 transduction in mouse retina. 
(A) WB analysis of eyecup lysates from C57BL/6J 2 months following subretinal injection of single and triple AAV2/8 vectors encoding 
for ED under the control of the ubiquitous CMV promoter. α-3xflag, WB with anti-3xflag antibodies; α-β-Tubulin, WB with anti-β-
Tubulin antibodies, used as loading control. Neg, lysates from eyecups following injection with PBS. The molecular weight ladder is 
depicted on the left, 100-150 µg of proteins were loaded. The arrow on the left indicates the full-length ED.  S1-12: lysates from eyecups 
injected subretinally with single CMV-ED-AAV: T1-14: lysates from eyecups injected subretinally with triple CMV-ED-AAVs. Neg, 
lysates  of eyecups following injection with PBS. 
(B) Densitometric values of ED bands in (A). To compare data across different experiments, in each WB the average intensity of the 
bands deriving from single AAV transduced eye was set as 1 and the intensity of triple AAVs transduced eye was divided by that of 
single AAV transduced eye and calculated accordingly. S1-12: lysates from eyecups injected subretinally with single CMV-ED-AAV. 
T1-14: lysates from eyecups injected subretinally with triple CMV-ED-AAVs. 
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Figure S4. Comparison between single and triple IRBP-ED-AAV2/8 transduction in mouse retina. 
(A) WB analysis of eyecup lysates from C57BL/6J 2 months following subretinal injection of single and triple AAV2/8 vectors encoding 
for ED under the control of the PR specific IRBP promoter. α-3xflag, WB with anti-3xflag antibodies; α-β-Tubulin, WB with anti-β-
Tubulin antibodies, used as loading control. Neg, lysates from eyecups following injection with PBS. The molecular weight ladder is 
depicted on the left, 200 µg of proteins were loaded. The arrow on the left indicates the full-length ED. S1-6, lysates from eyecups 
injected subretinally with single IRBP-ED-AAV. T1-8, lysates from eyecups injected subretinally with triple IRBP-ED-AAVs. Neg, 
lysates  of eyecups following injection with PBS. 
 (B) Densitometric values of ED bands in (A). To compare data across different experiments, in each WB the average intensity of the 
bands deriving from single AAV transduced eye was set as 1 and the intensity of triple AAVs transduced eye was divided by that of 
single AAV transduced eye and calculated accordingly. S1-6: lysates from eyecups injected subretinally with single IRBP-ED-AAV. T1-
8: lysates from eyecups injected subretinally with triple IRBP-ED-AAVs. 
Primer name Sequence 
CDH A ctgccaactggggtatcttc 
CDH B ctgttggtaagcggcatact 
CDH C tcagcacgtgactggaattt 
CDH D acatcgtcgggattgtagcga 
CDH E gtaagtggccaccagttccct 
CDH F agaccatgacggcgactata 
mCDH wt Forw catcgtggccaaggatgacac 
mCDH wt rev gaatgctctgggaggtcgct 
ALMS A ctcctctacttcctccaccac 
ALMS B cttctacagccacaccgaga 
ALMS C tgcctcttcagtcagatggg 
ALMS D gccagcgtaggtgtgttcaa 
ALMS E cttctggctttgccttcgtc 
ALMS F aggttccttgggacgactac 
mALMS wt forw taggacgtgaccgtggatact 
mALMS wt rev gccttgtggacttcgtaagc 
h𝛽-ACTIN forw gcgagaagatgacccagatc 
h𝛽-ACTIN rev ggatagcacagcctggatag 
mGAPDH forw agcaaggacactgagcaagag 
mGAPDH rev gcagcgaactttattgatggt 
Table S1.  
List of primers used for Real-Time quantitative PCR. Fw: forward primer; Rev: 
reverse primer; wt: wild type. 
